Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 11/20 | 0.62 |
| ▸ | DBF4 | Q9UBU7 | 11/20 | 0.62 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24419444 | 0.88 | CDC7 (0.52) | CDC7DBF4TRPM8MAPTMEN1 | |
| SCHEMBL24419187 | 0.88 | CDC7 (0.64) | CDC7DBF4TRPM8MAPTMEN1 | |
| SCHEMBL24419445 | 0.86 | TRPM8 (0.47) | CDC7DBF4TRPM8MAPTMEN1 | |
| SCHEMBL24419168 | 0.85 | DHODH (0.47) | CDC7DBF4TRPM8MAPTMEN1 | |
| SCHEMBL24419449 | 0.83 | MEN1 (0.49) | CDC7DBF4TRPM8MAPTMEN1 | |
| SCHEMBL6338322 | 0.77 | TRPM8 (1.00) | CDC7DBF4TRPM8MAPTMEN1 | |
| SCHEMBL15049177 | 0.77 | TRPM8 (0.76) | CDC7DBF4TRPM8MAPTMEN1 | |
| SCHEMBL5240574 | 0.76 | CDC7 (1.00) | CDC7DBF4TRPM8MAPTMEN1 | |
| SCHEMBL8867589 | 0.76 | TRPM8 (1.00) | CDC7DBF4TRPM8MAPTMEN1 | |
| SCHEMBL15048962 | 0.76 | TRPM8 (1.00) | CDC7DBF4TRPM8MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3931191-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK | GALAPAGOS NV (BE) | 2023-10-04 | — | — | EP | disclosed |
| US-20220144823-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK | GALAPAGOS NV (BE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144823-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK | GALAPAGOS NV (BE) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144823-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK | PDXK, PASK, NADK | CDC7 3165/4885DBF4 4483/4885TRPM8 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.